Syn2bio (WAR:S2B) OCF Margin %: 0.00% (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:S2B Syn2bio SA WAR:S2B
11 GF Score
Price zł81.40
! 2 Warning Signs
View Full Analysis

What is Syn2bio OCF Margin %?

Syn2bio WAR:S2B +1.88% 11 OCF Margin % is 0.00% as of Sep. 2025. GuruFocus rates WAR:S2B with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 950 Biotechnology companies, Syn2bio ranks worse than 105263.05% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Syn2bio's Cash Flow from Operations for the six months ended in Sep. 2025 was zł-20.21 Mil. Syn2bio's Revenue for the six months ended in Sep. 2025 was zł0.00 Mil. Therefore, Syn2bio's OCF Margin % for the quarter that ended in Sep. 2025 was 0.00%.

As of today, Syn2bio's current OCF Yield % is -2.90%.

The historical rank and industry rank for Syn2bio's OCF Margin % or its related term are showing as below:


WAR:S2B's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -64.565
* Ranked among companies with meaningful OCF Margin % only.

Syn2bio OCF Margin % Related Terms

Syn2bio OCF Margin % Historical Data

* Premium members only.

The historical data trend for Syn2bio's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syn2bio OCF Margin % Chart

Syn2bio Annual Data
Trend Sep23 Sep24 Sep25
OCF Margin %
0.00 0.00 0.00

Syn2bio Semi-Annual Data
Sep23 Sep24 Sep25
OCF Margin % 0.00 0.00 0.00
WAR:S2B
11GF Score
Syn2bio SA WAR:S2B
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syn2bio OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Syn2bio's OCF Margin for the fiscal year that ended in Sep. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Sep. 2025 )/Revenue (A: Sep. 2025 )
=-20.21/0
= %

Syn2bio's OCF Margin for the quarter that ended in Sep. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=-20.21/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Syn2bio (WAR:S2B) has a OCF Margin % of 0.00% as of Sep. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Syn2bio and its competitors. According to the industry distribution chart, Syn2bio ranks #999999 out of 950 companies in the Biotechnology industry.
Is Syn2bio's OCF Margin % too high?
Syn2bio's current OCF Margin % is 0.00%. Based on the distribution chart, Syn2bio ranks #999999 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Syn2bio has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Syn2bio's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Syn2bio ranks #999999 out of 950 companies for OCF Margin %. This places Syn2bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Syn2bio and its competitors. Syn2bio's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn2bio stock overvalued right now?
Syn2bio (WAR:S2B) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Syn2bio's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Syn2bio (WAR:S2B), the current OCF Margin % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syn2bio Business Description

Address ul. Jozefa Piusa Dziekonskiego 3, Warszawa, POL, 00-728
Syn2bio SA is a Polish biotech company that develops radiopharmaceuticals. It specializes in developing a cardiac biomarker for diagnosing heart conditions like coronary artery disease through myocardial perfusion imaging. The company's flagship product is the SYN2 cardiotracer. It is applied in the detection of perfusion disorders, evaluation of patients after myocardial infarction or with ischemic heart disease, and assessment of atherosclerotic changes in coronary arteries.
11GF Score

Get the complete analysis for WAR:S2B

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł81.40
Price